Overactive bladder
Drug research and approvals for overactive bladder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 77 studies of overactive bladder are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 77
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 3
Recruiting Now
Newest start dates first, of 77 recruiting on ClinicalTrials.gov ↗- Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson DiseaseNCT07187466 · Phase 4 · VA Office of Research and Development · starts Nov 9, 2026
- Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive BladderNCT07773532 · Not reported · Bagcilar Training and Research Hospital · starts Nov 2, 2026
- Peroneal Transcutaneous Neuromodulation in Children With Overactive BladderNCT07939061 · Not applicable · General University Hospital, Prague · starts Sep 3, 2026
- Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone…NCT07662824 · Not applicable · Mayo Clinic · starts Aug 20, 2026
- Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive BladderNCT07540273 · Not applicable · SEZGIN · starts Aug 15, 2026
- Electroacupuncture as a Treatment for Refractory Overactive BladderNCT07124390 · Not applicable · Chelsea and Westminster NHS Foundation Trust · starts Aug 15, 2026
- RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of…NCT07553065 · Phase 2 · Vensica Therapeutics Ltd. · starts Aug 14, 2026
- Does Use of a Pre-Procedure Educational Video for Urodynamic Testing Reduces Anxiety?NCT07740629 · Not applicable · Yair Daykan · starts Aug 1, 2026
- Self-Start Triage Model for Post-Botox® Lower Urinary Tract SymptomsNCT07648290 · Early Phase 1 · The Cleveland Clinic · starts Jul 31, 2026
- Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead PlacementNCT04527445 · Not applicable · Loma Linda University · starts Jun 1, 2026
How Its Trials Ended
794 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 188 whose ending is known, 51% met their primary endpoint, 2% missed it and 47% stopped early.
- Completed, result not reported38649%
- Status unknown11314%
- Ongoing10713%
- Met its primary endpoint9612%
- Stopped: other or unclear405%
- Stopped: enrollment or feasibility304%
- Stopped: lack of efficacy61%
- Stopped: sponsor or business decision51%
- Missed its primary endpoint41%
- Stopped: safety41%
- Stopped: funding30%
Trials Authorized in Canada
The 10 newest of 13; search them all in Canada trials| Aug 19, 2020 | A phase 3,double-blind,randomized,multicentre,parallel group,placebo-controlled sequential dose titration study to evaluate efficacy, safety and…Mirabegron | Astellas Pharma | Closed |
| Apr 17, 2019 | A phase 3 double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy, safety and tolerability of vibegron in men with overactive…Vibegron (RVT-901) | Urovant Sciences GmbH | Closed |
| Oct 5, 2018 | A phase 2, multicenter, randomized, double-blind, placebo-controlled, single-treatment, 2-stage, dose-finding study evaluating the efficacy and safety of botox…Botox | AbbVie | Closed |
| Apr 20, 2018 | An international phase 3, randomized, double-blind, active (tolterodine)-controlled multicenter extension study to evaluate the long-term safety and efficacy…Vibegron (RVT-901, MK-4618) | Urovant Sciences GmbH | Ongoing |
| Apr 20, 2018 | An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of…Vibegron (RVT-901, MK-4618) | Urovant Sciences GmbH | Closed |
| Nov 5, 2015 | A study to compare the effect of fesotrodine 4mg and 8mg and oxybutynin 5mg twice daily after steady state dosing versus placebo in subjects over age of 75…Fesoterodine-oxybutynin | Governors Of The University Of Alberta | Closed |
| Oct 20, 2015 | Randomized cross-over study of fesoterodine on urgency episodes in parkinson's disease population.Fesoterodine | Dr. Lysanne Campeau | Pending |
| Aug 18, 2015 | Efficacité et tolérabilité de la fésotérodine chez les enfants atteints de vessie hyperactive: phase d¿extension.Fesoterodine | Chu De QuéBec-Université Laval | Ongoing |
| Dec 17, 2014 | A phase 4, double-blind, randomized, placebo-controlled, parallel group, multi-center study to evaluate the efficacy, safety, and tolerability of mirabegron in…Myrbetriq (mirabegron) | Astellas Pharma | Closed |
| Sep 18, 2014 | Efficiency and tolerance of fesoterodin and oxybutynin in children with a hyperactive bladder: a comparative studyfesoterodine/ oxybutynin | Centre Hospitalier De L’Université Laval | Ongoing |
Medicines Authorised in the EU
Newest first| Jun 27, 2024 | ObgemsaVibegron | Pierre Fabre Medicament | EMA ↗ |
| Dec 20, 2012 | BetmigaMirabegron | Astellas Pharma Europe B.V. | EMA ↗ |
| Oct 22, 2004 | EmselexDarifenacin hydrobromide | pharmaand GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA